{"prompt": "['Trelagliptin-4002', 'Page 16 of 66', 'Version 2.0', 'July 5, 2017', 'Rationale for the number of planned study subjects:', 'In this clinical study, to discuss the changes in the total score for all questions in the DTR-QOL', 'Questionnaire from the baseline (Week 0) to the end of the treatment period, as the primary', 'endpoint, mean changes in the daily DPP-4 inhibitor and trelagliptin groups were assumed as 14.4%', 'and 19.0%, respectively. The mean change in the daily DPP-4 inhibitor group was assumed by', 'reference to the data on a sodium glucose transporter 2 (SGLT2) inhibitor, from the previous', 'research; and that in trelagliptin group was assumed by reference to the data from the validation trial', \"of the DTR-QOL Questionnaire. The common SD was assumed as 12.1' % considering the former\", 'assumption. When 5% of significance level (two-sided) is based for the analysis of the primary', 'endpoint, 110 subjects per group would be needed to ensure 80% power in comparisons between the', 'trelagliptin group and daily DPP-4 inhibitor group. As this is a study on treatment for type 2 diabetes', 'with DPP-4 inhibitors currently used in the medical setting, the number of randomized subjects was', 'established as 120 subjects per group, for a total of 240 subjects, assuming a type 2 diabetes', 'treatment discontinuation rate of 8%*.', '*Based on the results for Topic 2 of the \"Strategic Studies on the Prevention of Diabetes\"', '(JDOIT-2), the annual discontinuation rate for the \"usual care group\" without intervention is', 'approximately 8%.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 17 of 66', 'Version 2.0', 'July 5, 2017', '3.0', 'ABBREVIATION', 'AE', 'adverse event', 'COI', 'conflict of interest', 'CRO', 'contract research organization', 'DTSQ', 'Diabetes Treatment Satisfaction Questionnaire', 'DTR-QOL', 'Diabetes Therapy-Related QOL', 'FDA', 'US Food and Drug Administration', 'GCP', 'Good Clinical Practice', 'ICH', 'International Conference on Harmonization of Technical', 'Requirement for Registration on Pharmaceuticals for Human Use', 'MHRA', 'Medicines and Healthcare Products Regulatory Agency', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'QOL', 'Quality Of Life', 'SAE', 'serious adverse event', 'SAP', 'statistical analysis plan', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 18 of 66', 'Version 2.0', 'July 5,10', '4.0', 'INTRODUCTION', '4.1', 'Background', 'The aim of diabetes treatment is to maintain Quality of Life (QOL) similar to that of healthy people', 'and continue the same QOL for life as that of healthy people\u00b9 Well controlled blood glucose, lipid', 'and blood pressure levels to prevent complications in the early stages and greatly influence the', \"patients' QOL and prognoses. One of the characteristics of diabetes is a tendency of frequent\", 'treatment discontinuation because a patient tends to be unaware of his/her disease even after a', 'diagnosis of diabetes due to limited subjective symptoms during the early stages without notable', 'complications. However, in diabetes treatment, prevention of complications or slow disease', 'progression cannot be expected unless the patient is committed to the treatment; therefore, the key', \"point in diabetes treatment is to improve the patients' QOL to enable continued management of\", 'diabetes. On the other hand, discontinuation of diabetes treatment leads to progression of disease', \"complications and poor QOL. Patients' understanding of the treatment and the relationship between\", 'patients and medical personnel are important 2) The research using an auto-recording system', 'captured medication use reported that the level of compliance is decreased as dosing frequency', 'increased 3) In this context, to minimize the dosing frequency (number of tablets) is expected to', 'contribute to the improvement in the QOL and treatment satisfaction.', 'Dipeptidyl peptidase 4 (DPP-4) inhibitors inhibit degradation of gastrointestinal hormones GIP and', 'GLP-1, and thereby, enhance incretin effects glucose-level-dependently, and consequently decrease', 'blood glucose. In Japan, the first DPP-4 inhibitor was approved in December 2009. Since then, many', '\"daily-dosing\" DPP-4 inhibitors have been approved one after another which required to be taken', 'every day. In March 2015, trelagliptin was approved as the world\\'s first \"weekly-dosing\" DPP-4', 'inhibitor. In the use of trelagliptin, benefits of improving medication adherence are expected due to', 'less frequent dosing compared with existing oral glucose-lowering medications, especially in', 'patients who are starting oral glucose-lowering monotherapy.', '4.2', 'Rationale for the proposed study', 'QOL study in patients with type 2 diabetes starting treatment with oral glucose-lowering', 'medications can be expected to provide useful rationales in choosing a therapeutic medication', 'corresponding to various lifestyles of patients. DPP-4 inhibitors, including \"daily-dosing\" products,', 'have presented limited evidence regarding effects on the QOL of diabetes patients.', 'Accordingly, this study has been proposed to assess trends in the reduction of treatment burden using', 'the Diabetes Treatment Satisfaction Questionnaire (DTSQ). Also, to assess changes and trends in the', 'QOL at pre- and post-treatment of trelagliptin or a daily DPP-4 inhibitor in diabetes patients solely', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}